In a striking case of corporate déjà vu, South African pharmaceutical firm Adcock Ingram is once again the subject of a foreign takeover bid. However, the script has been flipped. Bidvest, the conglomerate that positioned itself as the company’s patriotic saviour over a decade ago, is now orchestrating its sale to an overseas partner. This culminates in a patient power…